Longitudinal Changes of Fundus Autofluorescence and Correlation With Visual Acuity in <i>ABCA4</i> -Associated Stargardt Disease
Characteristics other than DAF area (e.g., flecks presence) may influence VA. Some patients remained DDAF free longitudinally and thus would be excluded in STGD1 trials that use DDAF as the primary endpoint. The cross-sectional relationship between DAF and VA confirmed the association of VA with retinal pigment epithelium (RPE) structure. The lack of a significant association between growth in DAF areas with change in VA over follow-up points to challenges resulting from slow progression and large VA variability. Exploring outcome measures from other modalities is warranted for designing STGD1 trials.
Authors
- S. K. West
- EI Traboulsi
- Rupert W. Strauß (ORCID: https://orcid.org/0000-0002-2982-6370)
- David G. Birch (ORCID: https://orcid.org/0000-0002-6594-2897)
- E. Zrenner
- Folahan Adesola Ibukun
- Janet S. Sunness (ORCID: https://orcid.org/0000-0001-8823-0780)
- AV Cideciyan
- Xiangrong Kong (ORCID: https://orcid.org/0009-0000-2340-943X)
- Muhammad Jehanzeb Khan
- Zainab Rustam (ORCID: https://orcid.org/0000-0001-8686-3517)
- Michael Ip
- Isabelle S. Audo
- SriniVas Sadda
- Alexander Ho
- Paul Bernstein
- Michel Michaelides
Institutions
- Greater Baltimore Medical Center (US)
- Centre National de la Recherche Scientifique (FR)
- Cleveland Clinic (US)
- Institut de la Vision (FR)
- Penn Presbyterian Medical Center (US)
- Johns Hopkins University (US)
- Inserm (FR)
- University of Basel (CH)
- Medical University of Graz (AT)
- University of Utah (US)
- Sorbonne Université (FR)
- Doheny Eye Institute (US)
- Kepler Universitätsklinikum (AT)
- Retina Foundation of the Southwest (US)
- STZ eyetrial (DE)
- Moorfields Eye Hospital (GB)
- Eye Institute of Utah (US)
- Cleveland Eye Clinic (US)
- University College London (GB)
- University of Pennsylvania (US)
- University of Tübingen (DE)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1167/iovs.67.3.6
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Research to Prevent Blindness
- Amgen
- Pfizer
- Biogen
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Regeneron Pharmaceuticals
- Alimera Sciences
- Apellis Pharmaceuticals
- Carl Zeiss Meditec AG
- Astellas Pharma
- Heidelberg Engineering
- National Institutes of Health
- Genentech
- Samsung
- Allergan
- Janssen Pharmaceuticals